Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells

Oncogene

Volumn 28, Issue 30, 2009, Pages 2697-2709

  Argast, G M ^a   Croy, C H ^a   Couts, K L ^a   Zhang, Z ^b   Litman, E ^a   Chan, D C ^b   Ahn, N G ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

B Raf; Melanoma; Plexin; Semaphoring; Tumor suppressor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLEXIN; PLEXIN B1; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MIGRATION INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR CHAPERONES; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR SUPPRESSOR PROTEINS;

EID: 68149160391     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.133     Document Type: Article

References (54)

1. Aurandt J, Vikis HG, Gutkind JS, Ahn N, Guan KL. (2002). The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc Natl Acad Sci USA 99: 12085-12090.
2. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. (2004). Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res 64: 5212-5224.
3. Basile JR, Castilho RM, Williams VP, Gutkind JS. (2006). Semaphorin 4D provides a link between axon guidance processes and tumorinduced angiogenesis. Proc Natl Acad Sci USA 103: 9017-9022.
4. Basile JR, Gavard J, Gutkind JS. (2007). Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem 282: 34888-34895.
5. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC et al. (2004). Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114: 1260-1271.
6. Bloethner S, Chen B, Hemminki K, Mü ller-Berghaus J, Ugurel S, Schadendorf D et al. (2005). Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 26: 1224-1232.
7. Bogenrieder T, Herlyn M. (2002). Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol 44: 1-15.
8. Breitling R, Armengaud P, Amtmann A, Herzyk P. (2004). Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92.
9. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R et al. (2002). BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000.
10. Charest PG, Firtel RA. (2007). Big roles for small GTPases in the control of directed cell movement. Biochem J 401: 377-390.
11. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. (2004). Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 23: 5131-5137.
12. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM et al. (2005). Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105: 4321-4329.
13. Cox AD, Brtva TR, Lowe DG, Der CJ. (1994). R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells. Oncogene 9: 3281-3288.
14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
15. Dhomen N, Marais R. (2007). New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17: 31-39.
16. Dickson BJ. (2001). Rho GTPases in growth cone guidance. Curr Opin Neurobiol 11: 103-110.
17. Driessens MH, Hu H, Nobes CD, Self A, Jordens I, Goodman CS et al. (2001). Plexin-B semaphorin receptors interact directly with active Rac and regulate the actin cytoskeleton by activating Rho. Curr Biol 11: 339-344.
18. Fujisawa H. (2004). Discovery of semaphorin receptors, neuropilin and plexin, and their functions in neural development. J Neurobiol 59: 24-33.
19. Fukata M, Nakagawa M, Kaibuchi K. (2003). Roles of Rho-family GTPases in cell polarisation and directional migration. Curr Opin Cell Biol 15: 590-597.
20. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D et al. (2002). The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 4: 720-724.
21. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202.
22. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R et al. (2006). Metastatic potential of melanomas defined by specificgene expression profiles with no BRAF signature. Pigment Cell Res 19: 290-302.
23. Hsu MY, Elder DE, Herlyn M. (1999). Melanoma: the Wistar melanoma (WM) cell lines. Human Cell Culture 1: 259-274.
24. Ito Y, Oinuma I, Katoh H, Kaibuchi K, Negishi M. (2006). Sema4D/plexin-B1 activates GSK-3beta through R-Ras GAP activity, inducing growth cone collapse. EMBO Rep 7: 704-709.
25. Johansson P, Pavey S, Hayward N. (2007). Conflrmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 20: 216-221.
26. Keely PJ, Rusyn EV, Cox AD, Parise LV. (1999). R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells. J Cell Biol 145: 1077-1088.
27. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L et al. (2004). Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64: 1008-1015.
28. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. (2002). Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci USA 99: 3052-3057.
29. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J. (1997). R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 7: 63-70.
30. Mora N, Rosales R, Rosales C. (2007). R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunol Immunother 56: 535-544.
31. Nakada M, Niska JA, Tran NL, McDonough WS, Berens ME. (2005). EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol 167: 565-576.
32. Negishi M, Oinuma I, Katoh H. (2005). Plexins: axon guidance and signal transduction. Cell Mol Life Sci 62: 1363-1371.
33. Nishigaki M, Aoyagi K, Danjoh I, Fukaya M, Yanagihara K, Sakamoto H et al. (2005). Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res 65: 2115-2124.
34. Oinuma I, Ishikawa Y, Katoh H, Negishi M. (2004a). The Semaphorin 4D receptor Plexin-B1 is a GTPase activating protein for R-Ras. Science 305: 862-865.
35. Oinuma I, Katoh H, Negishi M. (2004b). Molecular dissection of the semaphorin 4D receptor plexin-B1-stimulated R-Ras GTPaseactivating protein activity and neurite remodeling in hippocampal neurons. J Neurosci 24: 11473-11480.
36. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
37. Osada M, Tolkacheva T, Li W, Chan TO, Tsichlis PN, Saez R et al. (1999). Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular transformation, adhesion, and survival. Mol Cell Biol 19: 6333-6344.
38. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067.
39. Perrot V, Vazquez-Prado J, Gutkind JS. (2002). Plexin B regulates Rho through the guanine nucleotide exchange factors leukemiaassociated Rho GEF (LARG) and PDZ-RhoGEF. J Biol Chem 277: 43115-43120.
40. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19-20.
41. Rincon-Arano H, Rosales R, Mora N, Rodriguez-Castaneda A, Rosales C. (2003). R-Ras promotes tumor growth of cervical epithelial cells. Cancer 97: 575-585.
42. Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G et al. (2007). Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res 13: 1115-1122.
43. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65: 2412-2421.
44. Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C et al. (2007). Lack of extracellular signal-regulated kinase mitogenactivated protein kinase signaling shows a new type of melanoma. Cancer Res 67: 1502-1512.
45. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
46. Swiercz JM, Kuner R, Behrens J, Offermanns S. (2002). Plexin-B1 directly interacts with PDZ-RhoGEF/LARG to regulate RhoA and growth cone morphology. Neuron 35: 51-63.
47. Swiercz JM, Worzfeld T, Offermanns S. (2008). ErbB-2 and Met reciprocally regulate cellular signaling via plexin-B1. J Biol Chem 283: 1893-1901.
48. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR et al. (2003). TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124.
49. Tian F, DaCosta Byfield S, Parks WT, Yoo S, Felici A, Tang B et al. (2003). Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 63: 8284-8292.
50. Vikis HG, Li W, Guan KL. (2002). The plexin-B1/Rac interaction inhibits PAK activation and enhances Sema4D ligand binding. Genes Dev 16: 836-845.
51. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
52. Wong OG, Nitkunan T, Oinuma I, Zhou C, Blanc V, Brown RS et al. (2007). Plexin-B1 mutations in prostate cancer. Proc Natl Acad Sci USA 104: 19040-19045.
53. Yu Y, Feig LA. (2002). Involvement of R-Ras and Ral GTPases in estrogen-independent proliferation of breast cancer cells. Oncogene 21: 7557-7568.
54. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD et al. (2005). Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 58: 1163-1169.